Search

Your search keyword '"VAN DEN BENT, Martin J."' showing total 1,369 results
Start Over Author "VAN DEN BENT, Martin J."
1,369 results on '"VAN DEN BENT, Martin J."'

101. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection

Author

Capper, David; https://orcid.org/0000-0003-1945-497X, Reifenberger, Guido, French, Pim J, Schweizer, Leonille; https://orcid.org/0000-0002-4649-2587, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Touat, Mehdi, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Euskirchen, Philipp; https://orcid.org/0000-0002-9138-805X, Haberler, Christine; https://orcid.org/0000-0003-1016-0545, Hegi, Monika E, Brandner, Sebastian; https://orcid.org/0000-0002-9821-0342, Le Rhun, Émilie; https://orcid.org/0000-0002-9408-3278, Rudà, Roberta, Sanson, Marc, Tabatabai, Ghazaleh; https://orcid.org/0000-0002-3542-8782, Sahm, Felix; https://orcid.org/0000-0001-5441-1962, Wen, Patrick Y, Wesseling, Pieter, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, van den Bent, Martin J; https://orcid.org/0000-0001-5710-5127, Capper, David; https://orcid.org/0000-0003-1945-497X, Reifenberger, Guido, French, Pim J, Schweizer, Leonille; https://orcid.org/0000-0002-4649-2587, Weller, Michael; https://orcid.org/0000-0002-1748-174X, Touat, Mehdi, Niclou, Simone P; https://orcid.org/0000-0002-3417-9534, Euskirchen, Philipp; https://orcid.org/0000-0002-9138-805X, Haberler, Christine; https://orcid.org/0000-0003-1016-0545, Hegi, Monika E, Brandner, Sebastian; https://orcid.org/0000-0002-9821-0342, Le Rhun, Émilie; https://orcid.org/0000-0002-9408-3278, Rudà, Roberta, Sanson, Marc, Tabatabai, Ghazaleh; https://orcid.org/0000-0002-3542-8782, Sahm, Felix; https://orcid.org/0000-0001-5441-1962, Wen, Patrick Y, Wesseling, Pieter, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, and van den Bent, Martin J; https://orcid.org/0000-0001-5710-5127

Abstract

The mainstay of treatment for adult patients with gliomas, glioneuronal and neuronal tumors consists of combinations of surgery, radiotherapy, and chemotherapy. For many systemic cancers, targeted treatments are a part of the standard of care, however, the predictive significance of most of these targets in central nervous system (CNS) tumors remains less well-studied. Despite that, there is increasing use of advanced molecular diagnostics that identify potential targets, and tumor-agnostic regulatory approvals on targets also present in CNS tumors have been granted. This raises the question of when and for which targets it is meaningful to test in adult patients with CNS tumors. This evidence-based guideline reviews the evidence available for targeted treatment for alterations in the RAS/MAPK pathway (BRAF, NF1), in growth factor receptors (EGFR, ALK, fibroblast growth factor receptor (FGFR), neurotrophic tyrosine receptor kinase (NTRK), platelet-derived growth factor receptor alpha, and ROS1), in cell cycle signaling (CDK4/6, MDM2/4, and TSC1/2) and altered genomic stability (mismatch repair, POLE, high tumor mutational burden (TMB), homologous recombination deficiency) in adult patients with gliomas, glioneuronal and neuronal tumors. At present, targeted treatment for BRAF p.V600E alterations is to be considered part of the standard of care for patients with recurrent gliomas, pending regulatory approval. For approved tumor agnostic treatments for NTRK fusions and high TMB, the evidence for efficacy in adult patients with CNS tumors is very limited, and treatment should preferably be given within prospective clinical registries and trials. For targeted treatment of CNS tumors with FGFR fusions or mutations, clinical trials are ongoing to confirm modest activity so far observed in basket trials. For all other reviewed targets, evidence of benefit in CNS tumors is currently lacking, and testing/treatment should be in the context of available clinical trials.

Published
2023

102. Independent prognostic impact of DNA methylation class and chromosome 1p loss in WHO grade 2 and 3 meningioma undergoing adjuvant high-dose radiotherapy: comprehensive molecular analysis of EORTC 22042-26042

Author

Maas, Sybren L N; https://orcid.org/0000-0002-8745-4405, Sievers, Philipp; https://orcid.org/0000-0003-3237-6021, Weber, Damien C, Weller, Michael; https://orcid.org/0000-0002-1748-174X, van den Bent, Martin J; https://orcid.org/0000-0001-5710-5127, Mair, Maximilian J; https://orcid.org/0000-0002-6537-3874, Kros, Johan M; https://orcid.org/0000-0002-4727-0724, Carparrotti, Fransesca, von Deimling, Andreas; https://orcid.org/0000-0002-5863-540X, Salvador, Villà Freixa, Peerdeman, Saskia Marguerite, Casas-Martin, Jose, Gorlia, Thierry, Sahm, Felix; https://orcid.org/0000-0001-5441-1962, Preusser, Matthias; https://orcid.org/0000-0003-3541-2315, Maas, Sybren L N; https://orcid.org/0000-0002-8745-4405, Sievers, Philipp; https://orcid.org/0000-0003-3237-6021, Weber, Damien C, Weller, Michael; https://orcid.org/0000-0002-1748-174X, van den Bent, Martin J; https://orcid.org/0000-0001-5710-5127, Mair, Maximilian J; https://orcid.org/0000-0002-6537-3874, Kros, Johan M; https://orcid.org/0000-0002-4727-0724, Carparrotti, Fransesca, von Deimling, Andreas; https://orcid.org/0000-0002-5863-540X, Salvador, Villà Freixa, Peerdeman, Saskia Marguerite, Casas-Martin, Jose, Gorlia, Thierry, Sahm, Felix; https://orcid.org/0000-0001-5441-1962, and Preusser, Matthias; https://orcid.org/0000-0003-3541-2315

Published
2023

103. IDH1/2 wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to IDH1/2 wildtype glioblastomas

Author

van Opijnen, Mark P., Tesileanu, C. Mircea S., Dirven, Linda, van der Meer, Pim B., Wijnenga, Maarten M. J., Vincent, Arnaud J. P. E., Broekman, Marike L. D., Dubbink, Hendrikus J., Kros, Johan M., van Duinen, Sjoerd G., Smits, Marion, French, Pim J., van den Bent, Martin J., Taphoorn, Martin J. B., Koekkoek, Johan A. F., van Opijnen, Mark P., Tesileanu, C. Mircea S., Dirven, Linda, van der Meer, Pim B., Wijnenga, Maarten M. J., Vincent, Arnaud J. P. E., Broekman, Marike L. D., Dubbink, Hendrikus J., Kros, Johan M., van Duinen, Sjoerd G., Smits, Marion, French, Pim J., van den Bent, Martin J., Taphoorn, Martin J. B., and Koekkoek, Johan A. F.

Abstract

Background IDH1/2 wildtype (IDHwt) glioma WHO grade 2 and 3 patients with pTERT mutation and/or EGFR amplification and/or + 7/-10 chromosome gain/loss have a similar overall survival time as IDHwt glioblastoma patients, and are both considered glioblastoma IDHwt according to the WHO 2021 classification. However, differences in seizure onset have been observed. This study aimed to compare the course of epilepsy in the 2 glioblastoma subtypes. Methods We analyzed epilepsy data of an existing cohort including IDHwt histologically lower-grade glioma WHO grade 2 and 3 with molecular glioblastoma-like profile (IDHwt hLGG) and IDHwt glioblastoma patients. Primary outcome was the incidence proportion of epilepsy during the disease course. Secondary outcomes included, among others, onset of epilepsy, number of seizure days, and antiepileptic drug (AED) polytherapy. Results Out of 254 patients, 78% (50/64) IDHwt hLGG and 68% (129/190) IDHwt glioblastoma patients developed epilepsy during the disease (P = .121). Epilepsy onset before histopathological diagnosis occurred more frequently in IDHwt hLGG compared to IDHwt glioblastoma patients (90% vs 60%, P < .001), with a significantly longer median time to diagnosis (3.5 vs 1.3 months, P < .001). Median total seizure days was also longer for IDHwt hLGG patients (7.0 vs 3.0, P = .005), and they received more often AED polytherapy (32% vs 17%, P = .028). Conclusions Although the incidence proportion of epilepsy during the entire disease course is similar, IDHwt hLGG patients show a significantly higher incidence of epilepsy before diagnosis and a significantly longer median time between first seizure and diagnosis compared to IDHwt glioblastoma patients, indicating a distinct clinical course.

Published
2023

104. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Author

Baumert, Brigitta G, Hegi, Monika E, van den Bent, Martin J, von Deimling, Andreas, Gorlia, Thierry, Hoang-Xuan, Khê, Brandes, Alba A, Kantor, Guy, Taphoorn, Martin J B, Hassel, Mohamed Ben, Hartmann, Christian, Ryan, Gail, Capper, David, Kros, Johan M, Kurscheid, Sebastian, Wick, Wolfgang, Enting, Roelien, Reni, Michele, Thiessen, Brian, Dhermain, Frederic, Bromberg, Jacoline E, Feuvret, Loic, Reijneveld, Jaap C, Chinot, Olivier, Gijtenbeek, Johanna M M, Rossiter, John P, Dif, Nicolas, Balana, Carmen, Bravo-Marques, Jose, Clement, Paul M, Marosi, Christine, Tzuk-Shina, Tzahala, Nordal, Robert A, Rees, Jeremy, Lacombe, Denis, Mason, Warren P, and Stupp, Roger

Published
2016
Full Text
View/download PDF

108. Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence

Author

Draaisma, Kaspar, Tesileanu, C Mircea S, de Heer, Iris, Klein, Martin, Smits, Marion, Reijneveld, Jaap C, Clement, Paul M, de Vos, Filip Y F, Wick, Antje, Mulholland, Paul J, Taphoorn, Martin J B, Weller, Michael, Chinot, Olivier L, Kros, Johan M, Verschuere, Tina, Coens, Corneel, Golfinopoulos, Vassilis, Gorlia, Thierry, Idbaih, Ahmed, Robe, Pierre A, van den Bent, Martin J, French, Pim J, Medical psychology, Neurology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life, Radiology & Nuclear Medicine, Pathology, University of Zurich, and French, Pim J

Subjects
Cancer Research, Brain Neoplasms, Homozygote, 610 Medicine & health, Glioma, DNA Methylation, Prognosis, Magnetic Resonance Imaging, Isocitrate Dehydrogenase, 10040 Clinic for Neurology, DNA Repair Enzymes, Oncology, SDG 3 - Good Health and Well-being, Mutation, Humans, 2730 Oncology, 1306 Cancer Research, Neoplasm Recurrence, Local, DNA Modification Methylases, Sequence Deletion
Abstract

Purpose: Despite recent advances in the molecular characterization of gliomas, it remains unclear which patients benefit most from which second-line treatments. The TAVAREC trial was a randomized, open-label phase II trial assessing the benefit of the addition of the angiogenesis inhibitor bevacizumab to treatment with temozolomide in patients with a first enhancing recurrence of World Health Organization grade 2 or 3 glioma without 1p/19q codeletion. We evaluated the prognostic significance of genome-wide DNA methylation profiles and copy-number variations on the TAVAREC trial samples. Experimental Design: Isocitrate dehydrogenase (IDH) mutation status was determined via Sanger sequencing and IHC. DNA methylation analysis was performed using the MethylationEPIC BeadChip (Illumina) from which 1p/19q codeletion, MGMT promoter methylation (MGMT-STP27), and homozygous deletion of CDKN2A/B were determined. DNA methylation classes were determined according to classifiers developed in Heidelberg and The Cancer Genome Atlas (TCGA; “Heidelberg” and “TCGA” classifier respectively). Results: DNA methylation profiles of 122 samples were successfully determined. As expected, most samples were IDH-mutant (89/122) and MGMT promotor methylated (89/122). Methylation classes were prognostic for time to progression. However, Heidelberg methylation classes determined at time of diagnosis were no longer prognostic following enhancing recurrence of the tumor. In contrast, TCGA methylation classes of primary samples remained prognostic also following enhancing recurrence. Homozygous deletions in CDKN2A/B were found in 10 of 87 IDH-mutated samples and were prognostically unfavorable at recurrence. Conclusions: DNA methylome Heidelberg classification at time of diagnosis is no longer of prognostic value at the time of enhancing recurrence. CDKN2A/B deletion status was predictive of survival from progression of IDH-mutated tumors.

Published
2022
Full Text
View/download PDF

109. Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study

Author

Nowosielski, Martha, Gorlia, Thierry, Bromberg, Jacoline E.C., Sahm, Felix, Harting, Inga, Kickingereder, Philipp, Brandes, Alba A., Taphoorn, Martin J.B., Taal, Walter, Domont, Julien, Idbaih, Ahmed, Campone, Mario, Clement, Paul M., Weller, Michael, Fabbro, Michel, Le Rhun, Emilie, Platten, Michael, Golfinopoulos, Vassilis, van den Bent, Martin J., Bendszus, Martin, and Wick, Wolfgang

Published
2019
Full Text
View/download PDF

110. Preface

Author

Schiff, David, primary and van den Bent, Martin J., additional

Published
2018
Full Text
View/download PDF

111. Supplementary Data from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Author

Draaisma, Kaspar, primary, Tesileanu, C. Mircea S., primary, de Heer, Iris, primary, Klein, Martin, primary, Smits, Marion, primary, Reijneveld, Jaap C., primary, Clement, Paul M., primary, de Vos, Filip Y.F., primary, Wick, Antje, primary, Mulholland, Paul J., primary, Taphoorn, Martin J.B., primary, Weller, Michael, primary, Chinot, Olivier L., primary, Kros, Johan M., primary, Verschuere, Tina, primary, Coens, Corneel, primary, Golfinopoulos, Vassilis, primary, Gorlia, Thierry, primary, Idbaih, Ahmed, primary, Robe, Pierre A., primary, van den Bent, Martin J., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

112. Supplementary Figure from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges

Author

Chow, Laura Q.M., primary, Barlesi, Fabrice, primary, Bertino, Erin M., primary, van den Bent, Martin J., primary, Wakelee, Heather A., primary, Wen, Patrick Y., primary, Chiu, Chao-Hua, primary, Orlov, Sergey, primary, Chiari, Rita, primary, Majem, Margarita, primary, McKeage, Mark, primary, Yu, Chong-Jen, primary, Garrido, Pilar, primary, Hurtado, Felipe K., primary, Arratia, Pilar Cazorla, primary, Song, Yuanbo, primary, Branle, Fabrice, primary, Shi, Michael, primary, and Kim, Dong-Wan, primary

Published
2023
Full Text
View/download PDF

113. Supplementary Data from ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non–Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges

Author

Chow, Laura Q.M., primary, Barlesi, Fabrice, primary, Bertino, Erin M., primary, van den Bent, Martin J., primary, Wakelee, Heather A., primary, Wen, Patrick Y., primary, Chiu, Chao-Hua, primary, Orlov, Sergey, primary, Chiari, Rita, primary, Majem, Margarita, primary, McKeage, Mark, primary, Yu, Chong-Jen, primary, Garrido, Pilar, primary, Hurtado, Felipe K., primary, Arratia, Pilar Cazorla, primary, Song, Yuanbo, primary, Branle, Fabrice, primary, Shi, Michael, primary, and Kim, Dong-Wan, primary

Published
2023
Full Text
View/download PDF

114. Supplementary Figure from Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Author

Tesileanu, C. Mircea S., primary, Sanson, Marc, primary, Wick, Wolfgang, primary, Brandes, Alba A., primary, Clement, Paul M., primary, Erridge, Sara C., primary, Vogelbaum, Michael A., primary, Nowak, Anna K., primary, Baurain, Jean-Francois, primary, Mason, Warren P., primary, Wheeler, Helen, primary, Chinot, Olivier L., primary, Gill, Sanjeev, primary, Griffin, Matthew, primary, Rogers, Leland, primary, Taal, Walter, primary, Rudà, Roberta, primary, Weller, Michael, primary, McBain, Catherine, primary, van Linde, Myra E., primary, Aldape, Kenneth, primary, Jenkins, Robert B., primary, Kros, Johan M., primary, Wesseling, Pieter, primary, von Deimling, Andreas, primary, Hoogstrate, Youri, primary, de Heer, Iris, primary, Atmodimedjo, Peggy N., primary, Dubbink, Hendrikus J., primary, Brouwer, Rutger W.W., primary, van IJcken, Wilfred F.J., primary, Cheung, Kin Jip, primary, Golfinopoulos, Vassilis, primary, Baumert, Brigitta G., primary, Gorlia, Thierry, primary, French, Pim J., primary, and van den Bent, Martin J., primary

Published
2023
Full Text
View/download PDF

115. Supplementary Figure from Prognostic Significance of DNA Methylation Profiles at MRI Enhancing Tumor Recurrence: a Report from the EORTC 26091 TAVAREC Trial

Author

Draaisma, Kaspar, primary, Tesileanu, C. Mircea S., primary, de Heer, Iris, primary, Klein, Martin, primary, Smits, Marion, primary, Reijneveld, Jaap C., primary, Clement, Paul M., primary, de Vos, Filip Y.F., primary, Wick, Antje, primary, Mulholland, Paul J., primary, Taphoorn, Martin J.B., primary, Weller, Michael, primary, Chinot, Olivier L., primary, Kros, Johan M., primary, Verschuere, Tina, primary, Coens, Corneel, primary, Golfinopoulos, Vassilis, primary, Gorlia, Thierry, primary, Idbaih, Ahmed, primary, Robe, Pierre A., primary, van den Bent, Martin J., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

116. Supplementary Table 5 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

117. Supplementary Figure Legend from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

118. Suppl Text and Figures from Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)

Author

Wick, Wolfgang, primary, Gorlia, Thierry, primary, Bady, Pierre, primary, Platten, Michael, primary, van den Bent, Martin J., primary, Taphoorn, Martin J.B., primary, Steuve, Jonathan, primary, Brandes, Alba A., primary, Hamou, Marie-France, primary, Wick, Antje, primary, Kosch, Markus, primary, Weller, Michael, primary, Stupp, Roger, primary, Roth, Patrick, primary, Golfinopoulos, Vassilis, primary, Frenel, Jean-Sebastien, primary, Campone, Mario, primary, Ricard, Damien, primary, Marosi, Christine, primary, Villa, Salvador, primary, Weyerbrock, Astrid, primary, Hopkins, Kirsten, primary, Homicsko, Krisztian, primary, Lhermitte, Benoit, primary, Pesce, Gianfranco, primary, and Hegi, Monika E., primary

Published
2023
Full Text
View/download PDF

119. Appendix 2 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm

Author

van der Voort, Sebastian R., primary, Incekara, Fatih, primary, Wijnenga, Maarten M.J., primary, Kapas, Georgios, primary, Gardeniers, Mayke, primary, Schouten, Joost W., primary, Starmans, Martijn P.A., primary, Nandoe Tewarie, Rishie, primary, Lycklama, Geert J., primary, French, Pim J., primary, Dubbink, Hendrikus J., primary, van den Bent, Martin J., primary, Vincent, Arnaud J.P.E., primary, Niessen, Wiro J., primary, Klein, Stefan, primary, and Smits, Marion, primary

Published
2023
Full Text
View/download PDF

120. Supplementary Table 2 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

121. Online Figure 1 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm

Author

van der Voort, Sebastian R., primary, Incekara, Fatih, primary, Wijnenga, Maarten M.J., primary, Kapas, Georgios, primary, Gardeniers, Mayke, primary, Schouten, Joost W., primary, Starmans, Martijn P.A., primary, Nandoe Tewarie, Rishie, primary, Lycklama, Geert J., primary, French, Pim J., primary, Dubbink, Hendrikus J., primary, van den Bent, Martin J., primary, Vincent, Arnaud J.P.E., primary, Niessen, Wiro J., primary, Klein, Stefan, primary, and Smits, Marion, primary

Published
2023
Full Text
View/download PDF

122. Supplementary Figure 3 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

123. Data from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

124. Supplementary Figure 3 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

125. Supplementary Table S1 from Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

Author

Lassman, Andrew B., primary, Roberts-Rapp, Lisa, primary, Sokolova, Irina, primary, Song, Minghao, primary, Pestova, Ekaterina, primary, Kular, Rupinder, primary, Mullen, Carolyn, primary, Zha, Zheng, primary, Lu, Xin, primary, Gomez, Erica, primary, Bhathena, Anahita, primary, Maag, David, primary, Kumthekar, Priya, primary, Gan, Hui K., primary, Scott, Andrew M., primary, Guseva, Maria, primary, Holen, Kyle D., primary, Ansell, Peter J., primary, and van den Bent, Martin J., primary

Published
2023
Full Text
View/download PDF

126. Online Figure 2 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm

Author

van der Voort, Sebastian R., primary, Incekara, Fatih, primary, Wijnenga, Maarten M.J., primary, Kapas, Georgios, primary, Gardeniers, Mayke, primary, Schouten, Joost W., primary, Starmans, Martijn P.A., primary, Nandoe Tewarie, Rishie, primary, Lycklama, Geert J., primary, French, Pim J., primary, Dubbink, Hendrikus J., primary, van den Bent, Martin J., primary, Vincent, Arnaud J.P.E., primary, Niessen, Wiro J., primary, Klein, Stefan, primary, and Smits, Marion, primary

Published
2023
Full Text
View/download PDF

127. Supplementary Data from A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Author

Lassman, Andrew B., primary, Wen, Patrick Y., primary, van den Bent, Martin J., primary, Plotkin, Scott R., primary, Walenkamp, Annemiek M.E., primary, Green, Adam L., primary, Li, Kai, primary, Walker, Christopher J., primary, Chang, Hua, primary, Tamir, Sharon, primary, Henegar, Leah, primary, Shen, Yao, primary, Alvarez, Mariano J., primary, Califano, Andrea, primary, Landesman, Yosef, primary, Kauffman, Michael G., primary, Shacham, Sharon, primary, and Mau-Sørensen, Morten, primary

Published
2023
Full Text
View/download PDF

128. Supplementary Figure legends from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

129. Supplementary Figure 2 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

130. Supplementary Table 4 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

131. Supplementary Table 4 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

132. Supplementary Table 3 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

133. Supplementary Table 1 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

134. Supplementary Figure 2 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

135. Supplementary Table 2 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

136. Appendix 4 from Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm

Author

van der Voort, Sebastian R., primary, Incekara, Fatih, primary, Wijnenga, Maarten M.J., primary, Kapas, Georgios, primary, Gardeniers, Mayke, primary, Schouten, Joost W., primary, Starmans, Martijn P.A., primary, Nandoe Tewarie, Rishie, primary, Lycklama, Geert J., primary, French, Pim J., primary, Dubbink, Hendrikus J., primary, van den Bent, Martin J., primary, Vincent, Arnaud J.P.E., primary, Niessen, Wiro J., primary, Klein, Stefan, primary, and Smits, Marion, primary

Published
2023
Full Text
View/download PDF

137. Supplementary Figure 4 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

138. Supplementary Figure S2 from Detection of Aneuploidy in Cerebrospinal Fluid from Patients with Breast Cancer Can Improve Diagnosis of Leptomeningeal Metastases

Author

Angus, Lindsay, primary, Deger, Teoman, primary, Jager, Agnes, primary, Martens, John W.M., primary, de Weerd, Vanja, primary, van Heuvel, Irene, primary, van den Bent, Martin J., primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Bindels, Eric M.J., primary, Heitzer, Ellen, primary, Sleijfer, Stefan, primary, Jongen, Joost L.M., primary, and Wilting, Saskia M., primary

Published
2023
Full Text
View/download PDF

139. Supplementary Figure 1 from A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendroglial Brain Tumors: A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Gravendeel, Lonneke A., primary, Gorlia, Thierry, primary, Kros, Johan M., primary, Lapre, Lariesa, primary, Wesseling, Pieter, primary, Teepen, Johannes L., primary, Idbaih, Ahmed, primary, Sanson, Marc, primary, Smitt, Peter A.E. Sillevis, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

140. Supplementary Table 3 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

141. Supplementary Figure 1 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

142. Supplemental Tables and Figures from Comparison of Biomarker Assays for EGFR: Implications for Precision Medicine in Patients with Glioblastoma

Author

Lassman, Andrew B., primary, Roberts-Rapp, Lisa, primary, Sokolova, Irina, primary, Song, Minghao, primary, Pestova, Ekaterina, primary, Kular, Rupinder, primary, Mullen, Carolyn, primary, Zha, Zheng, primary, Lu, Xin, primary, Gomez, Erica, primary, Bhathena, Anahita, primary, Maag, David, primary, Kumthekar, Priya, primary, Gan, Hui K., primary, Scott, Andrew M., primary, Guseva, Maria, primary, Holen, Kyle D., primary, Ansell, Peter J., primary, and van den Bent, Martin J., primary

Published
2023
Full Text
View/download PDF

143. Supplementary Table 1 from MGMT-STP27 Methylation Status as Predictive Marker for Response to PCV in Anaplastic Oligodendrogliomas and Oligoastrocytomas. A Report from EORTC Study 26951

Author

van den Bent, Martin J., primary, Erdem-Eraslan, Lale, primary, Idbaih, Ahmed, primary, de Rooi, Johan, primary, Eilers, Paul H.C., primary, Spliet, Wim G.M., primary, den Dunnen, Wilfred F.A., primary, Tijssen, Cees, primary, Wesseling, Pieter, primary, Sillevis Smitt, Peter A.E., primary, Kros, Johan M., primary, Gorlia, Thierry, primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

144. Supplementary Figure S13 from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Author

Erdem-Eraslan, Lale, primary, van den Bent, Martin J., primary, Hoogstrate, Youri, primary, Naz-Khan, Hina, primary, Stubbs, Andrew, primary, van der Spek, Peter, primary, Böttcher, René, primary, Gao, Ya, primary, de Wit, Maurice, primary, Taal, Walter, primary, Oosterkamp, Hendrika M., primary, Walenkamp, Annemiek, primary, Beerepoot, Laurens V., primary, Hanse, Monique C.J., primary, Buter, Jan, primary, Honkoop, Aafke H., primary, van der Holt, Bronno, primary, Vernhout, René M., primary, Smitt, Peter A.E. Sillevis, primary, Kros, Johan M., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

146. Supplementary Table S1 from Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial

Author

Erdem-Eraslan, Lale, primary, van den Bent, Martin J., primary, Hoogstrate, Youri, primary, Naz-Khan, Hina, primary, Stubbs, Andrew, primary, van der Spek, Peter, primary, Böttcher, René, primary, Gao, Ya, primary, de Wit, Maurice, primary, Taal, Walter, primary, Oosterkamp, Hendrika M., primary, Walenkamp, Annemiek, primary, Beerepoot, Laurens V., primary, Hanse, Monique C.J., primary, Buter, Jan, primary, Honkoop, Aafke H., primary, van der Holt, Bronno, primary, Vernhout, René M., primary, Smitt, Peter A.E. Sillevis, primary, Kros, Johan M., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

147. Data from Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

Author

Gravendeel, Lonneke A.M., primary, Kouwenhoven, Mathilde C.M., primary, Gevaert, Olivier, primary, de Rooi, Johan J., primary, Stubbs, Andrew P., primary, Duijm, J. Elza, primary, Daemen, Anneleen, primary, Bleeker, Fonnet E., primary, Bralten, Linda B.C., primary, Kloosterhof, Nanne K., primary, De Moor, Bart, primary, Eilers, Paul H.C., primary, van der Spek, Peter J., primary, Kros, Johan M., primary, Sillevis Smitt, Peter A.E., primary, van den Bent, Martin J., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

148. Supplementary Figure 9 from Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

Author

Gravendeel, Lonneke A.M., primary, Kouwenhoven, Mathilde C.M., primary, Gevaert, Olivier, primary, de Rooi, Johan J., primary, Stubbs, Andrew P., primary, Duijm, J. Elza, primary, Daemen, Anneleen, primary, Bleeker, Fonnet E., primary, Bralten, Linda B.C., primary, Kloosterhof, Nanne K., primary, De Moor, Bart, primary, Eilers, Paul H.C., primary, van der Spek, Peter J., primary, Kros, Johan M., primary, Sillevis Smitt, Peter A.E., primary, van den Bent, Martin J., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

150. Supplementary Figure 10 from Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology

Author

Gravendeel, Lonneke A.M., primary, Kouwenhoven, Mathilde C.M., primary, Gevaert, Olivier, primary, de Rooi, Johan J., primary, Stubbs, Andrew P., primary, Duijm, J. Elza, primary, Daemen, Anneleen, primary, Bleeker, Fonnet E., primary, Bralten, Linda B.C., primary, Kloosterhof, Nanne K., primary, De Moor, Bart, primary, Eilers, Paul H.C., primary, van der Spek, Peter J., primary, Kros, Johan M., primary, Sillevis Smitt, Peter A.E., primary, van den Bent, Martin J., primary, and French, Pim J., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results